Scientific Program

12th International Conference on Cachexia, Sarcopenia & Muscle Wasting

Berlin, 06-08 Dec 2019 

Charite Umb logo

REGISTER

                                                                               Friday, 6 December 2019
9:00-10:30
A) Opening Session

“Prometheus” basic science key note lecture 
Didier Attaix (France)

“Hippocrates” clinical science key note lecture
Andrew Coats (UK)

Recent facts & figures: sarcopenia & frailty (the JCSM lecture)
Stephan von Haehling (Germany)

Recent facts & figures: Cachexia & SCWD
Stefan Anker (Germany)

10:30-11:00
Coffee Break

11:00-13:00
B) Novel targets parade

The role of brain CCR2 in cachexia or neuroinflammation and cancer cachexia
TBD

Novel tumor-derived mediators of cachexia
Mauricio Berriel Diaz (Germany)

Metastasis and cancer cachexia
Swarnali Acharyya (USA)

Epi-genomics landscapes in cancer cachexia
Søren Fisker-Schmidt (Germany)

Therapeutic effects of creatine supplementation and exercise in cachexia
TBD

Activating Mas receptor to reduce cachexia
Gordon Lynch (Australia)

Mechanism of p300 activation and mediation of muscle wasting in cancer cachexia
Yi-Ping Li (USA)

Targeting the ubiquitin-proteasome system to counteract cancer cachexia – update 2019
Volker Adams (Germany)

TBD

Receptor-modified approach on anorexia-cachexia syndrome with an emphasis of ghrelin-neuropeptide Y-orexin hunger system
Yasuhito Uezono (Japan)

 

C) Bone and muscle interactions in cachexia and sarcopenia

Musculoskeletal complications of cancer and its treatments
Andrea Bonetto (USA)

Bone-muscle crosstalk in bone metastatic cancer
David Wanning (USA)

Wnt pathway in bone-muscle crosstalk
TBD

Role of soluble factors in muscle/bone interactions
TBD

Role of muscle and bone factors in energetics and metabolism
Gustavo Duque (Australia)

Muscle-bone crosstalk – results from the experimental studies
TBD

Does testosterone play a key role in osteosarcopenia?
Giuseppe Rosano (UK)

Low muscle mass and strength as a risk factor for fracture – clinical studies
Jürgen Bauer(Germany)

Impact of the fracture on muscle strength and physical performance
Pawel Szulc (France)

13:15-14:15
Lunch Seminar

14:30-16:00
D) Cachexia, sarcopenia and frailty in acute illness: clinical discussion

Assessing muscle and fat mass using imaging and biomarker tests in the critical ill: practical approach
TBD

Critical-illness induced wasting of muscular fat tissue
Werner Z’Graggen (Switzerland)

Critical-illness acquired weakness (ICU-AW)
Tobias Wollersheim (Germany)

Outlook: additional critical illness induced neuromuscular dysfunctions
Joerg Schefold (Switzerland)

Nutritional interventions in the ICU: an overview
TBD

E) Myogenesis for cachexia / sarcopenia

Mesoangioblast-driven muscle regeneration in aging
Maurilio Sampaolesi (Belgium)

Twist1, myogenesis and cancer cachexia
Azeddine Atfi (USA)

The S100B/RAGE pathway in myogenesis impairment
GuglielmoSorci (Italy)

Myoparr, a novel mediator of muscle wasting
Kunihiro Tsuchida (Japan)

The relevance of studying old vs. young animals
Connie Jackaman (Australia)

 16:00-17:00
Coffee Break

16:05-16:55
Poster Session 1

16:10-16:50
Rapid Fire Abstracts Session 1

(8 abstracts / 5 min)

17:00-18:30
F) Cachexia in chronic illness: update 2019

Cachexia in chronic obstructive pulmonary disease
Annemie Schols (The Netherlands)

Cachexia and protein-energy wasting liver disease
Srinivasan Dasarathy(USA)

Diagnosis, treatment and prevention of cardiac cachexia in heart failure
Stephan von Haehling (Germany)

Liver cachexia
Matthias Plauth (Germany)

Anorexia and cachexia
Maurizio Muscaritoli (Italy)

G) Muscle stem cells and regeneration in sarcopenia and cachexia

Regulation of muscle stem cells and regeneration during aging in humans
TBD

Cross-talk between muscle stem cells, inflammation and fibrosis during muscle regeneration in aging
TBD

Therapeutic interventions targeting cellular communication in the aged stem cell niche
Jerome Feige (Switzerland)

Myogenic commitment in cancer cachexia
Denis Guttridge (USA)

Allogeneic cell therapy for muscle injury in phase III

Allogeneic cell therapy for muscle injury in phase III
Tobias Winkler(Germany)

18:30-19.30
Wine & Cheese Welcome Reception in Poster Area

Saturday, 7 December 2019

 8:00-8:45

Breakfast Seminar
Ken Fearon Career Café – Meet the Mentor
Coordinated by Mitja Lainscak, Slovenia


Statistical Seminar
Jennifer Le-Rademacher
Ruta Brazauskas

9:00-10:30
H) Symptoms of patients with cachexia and their therapy

Shortness of breath
TBD

Swallowing problems
Hidetaka Wakabayashi (Japan)

Pain
Florian Strasser (Switzerland)

Depression
Joanne Reid (Ireland)

Muscle weakness and fatigue: how to assess objectivity
Richard Dunne (USA)

I) Mitochondria: a nexus for muscle wasting and impaired metabolism

Mitochondrial dynamics in the regulation of muscle mass
Antonio Zorzano (Spain)

Oxidative stress impact on muscle mass and function
TBD

Feeding mitochondria to counteract cachexia
Klaske van Norren (The Netherlands)

Exercise and oxidative metabolism in muscle wasting
James Carson (USA)

Therapeutic interventions targeting mitochondria – clinical results
Michelangelo Mancuso (Italy)

10:30-11:30
Break

 10:35-11:25
Poster session 2

10:40-11:20

Rapid Fire Abstracts Session 2
(8 abstracts / 5 min)

 

11:30-13:00

J) Sarcopenia and frailty in chronic illness

Sarcopenia in chronic kidney disease and its therapy
Kamyar Kalantar-Zadeh (USA)

Sarcopenia in COPD and its therapy
Ramon Langen (The Netherlands)

Heart failure sarcopenia and adiposity paradox
Mitja Lainscak (Slovenia)

Frailty and muscle function in chronic illness
Luigi Ferrucci (USA)

Adipose tissue browning and vitamin D in chronic illness
Robert Mak (USA)

K) Cachexia, sarcopenia and frailty in acute illness: from mechanisms to therapy

Satellite cells and inflammation
TBD

The inflammatory “genomic storm” post trauma and sepsis – a driver of rapid muscle wasting
Scott Brakenridge (USA)

TBD
David Glass (USA)

Post-sepsis microenviroment alterations in skeletal muscle wasting
Jason Doles (USA)

Electrical stimulation as an intervention in the critically ill
Steffen Weber-Carstens (Germany)

Potential nutritional interventions to prevent acute muscle wasting
TBD

13:15-14:15
Lunch Seminar

 14:30-16:00

L) Late breaking clinical science and clinical trial update

The EFFORT study – effective to preserve muscle mass and functional outcomes in critically ill patients
Christian Stoppe (Germany)

TBD

TBD

TBD

TBD

 M) Sarcopenia and aging – diagnosis, exercise, nutrition

The SCWD consensus on sarcopenia
John Morley (USA)

Screening for sarcopenia
TBD

Low D3Cr muscle mass and health outcomes in older adults
Peggy Cawthon (USA)

Exercise as a treatment of frailty in hospital care
Mikel Izquierdo (Spain)

Treating sarcopenia in a rural community
Janice Lundy (USA)

Herbal medicine based nutrition

 

16:00-17:00

Coffee Break

16:05-16:55
Poster session 3

16:10-16:50
Rapid Fire Abstracts Session 3
(8 abstracts / 5 min)

 

17:00-19:00

N) Hot topic in muscle wasting

Molecular mechanisms and promising therapies in Muscle wasting
TBD

Mytho a novel player in autophagy and cancer
Marco Sandri (Italy)

Key facilitator proteins that mediate sarcolemma membrane repair have potential as therapeutics for muscle disease and injury
Noah Weisleder (USA)

An epigenetic mechanism suppresses muscle protein synthesis by regulation of ribosomal biogenesis in catabolic conditions TBD

Nix induced mitochondrial fission, mitophagy, and myocyte insulin resistance are abrogated by PKA phosphorylation
Joseph Gordon (Canada)

Tissue sodium accumulation and peripheral insulin sensitivity in maintenance hemodialysis patients
Talat Alp Ikizler (USA)

Apelin and sarcopenia of aging
TBD

Deacetylase inhibitors to treat muscle wasting
Vered Raz (The Netherlands)  

An update on the role of anabolic steroids in muscle wasting
Jeffrey Crawford (USA)

 

O) The fat and appetite session

An update on brown fat
Josep Argiles (ESP)

Brown fat and cancer cachexia: understanding interactive mechanisms
TBD

Measuring brown fat in humans
TBD

TLR4 involvement in adipose tissue loss in cancer cachexia
Miguel L. Batista (BR)    

Targeting the GDF15/MIC-1 pathway for anorexia/cachexia
Samuel Breit (AUS)

MC3R modulate locomotor activity, energy expenditure, and adiposity in mice
TBD

Mining the genetics of obesity in humans for novel opportunities against cachexia
TBD

The gap between existing large population data and the need of novel database relevant to cachexia
Melissa Miller (USA)

In-vivo screening platform to identify new pro-cachectic/anorectic tumor factors
Olivier Bezy (USA)

 

Sunday, 8 December 2019

 

 

7:30-8:20
Breakfast Seminar

Ken Fearon Career Café – Meet the Mentor
Coordinated by Mitja Lainscak, Slovenia

 

Statistical Seminar
Jennifer Le-Rademacher

Ruta Brazauskas

8:30-10:00

P) Neurological impact of sarcopenia

Neurophysiological basis of anorexia-cachexia syndrome
Toshihiko Yada (Japan)

Sarcopenia in neuromuscular diseases
Gabriele Siciliano (Italy)

Stroke and sarcopenia
Wolfram Doehner (GER)

Dementia and sarcopenia. A vicious circle
TBD

Mitochondrial impact on sarcopenia
Michelangelo Mancuso (Italy)

Brain wasting
Matthias Endres (Germany)

 Q) Young Investigators Awards Session – Clinical & Basic
(Finalists:  3 abstracts clinical / 3 abstracts basic)

Presentations will be selected from submitted abstracts. Each presenter has 10 min for presentation & 5 min for discussion by the panel of chairs & judges.

 10:00-11:00
Coffee Break

 10:05-10:55
Poster session 4

 11:00-12.30

R) Sex matters in cachexia

Multi-platform omics analyses document distinct phenotypes and mechanisms in cancer cachexia
Vickie Baracos (CAN)

Sex differences in imaging for cachexia
Steven Heymsfield (USA)

The role of estrogen in cachexia-induced metabolic disruptions
TBD

Sex-specific differences in treatment response in cancer cachexia
Jose Garcia (USA)

Sex specific phenotypes, mechanisms, and treatment response in mice and humans with pancreatic cancer
Teresa Zimmers (USA)

TBD

TBD

S) Cancer- and chemotherapy-induced wasting

Chemotherapy-induced metabolic abnormalities in cancer cachexia
Thomas O’Connell (USA)

Skeletal muscle adaptations to cancer and chemotherapy and the protective effects of exercise
Micheal Toth (USA)

Effects of Activin inhibition on chemotherapy-induced cachexia
Juha Hulmi (Finland)

Chemotherapy to delay/counteract cachexia
Fabio Penna (Italy)

Cancer mediated cardiac wasting – update 2019
Stephan Herzig (Germany)

TBD
Bette Caan (USA)

12:30-13:00
Break

13:00-13:45

T) Frailty in major chronic illnesses

Impact and definition
TBD

Screening tools
TBD

Management
TBD

13:45-15:15

U) Mind-bending therapeutic ideas to enhance muscle functionality

Spider dragline silk as a potential component of artificial muscle
TBD

Resilience training and results in war veterans who have lost limbs
TBD

Muscle satellite cells and their role in regenerative medicine
TBD

Making patients fat again: good idea? If so, how?
Andrew Coats (UK)

Data-driven identification and optimization of new medicines for cancer cachexia
Ben Zeskind (USA)

 

15:15-16:00

V) Highlights Session

 Highlights Basic Science

Highlights Clinical Science & Nutrition

Highlights Treatment

Poster Awards
Young Investigator Awards
Farewell